- Home
- BKE vs VRNA Comparison
BKE vs VRNA Comparison
Compare BKE & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- VRNA
- Stock Information
- Founded
- BKE 1948
- VRNA 2005
- Country
- BKE United States
- VRNA United Kingdom
- Employees
- BKE N/A
- VRNA N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- BKE Consumer Discretionary
- VRNA Health Care
- Exchange
- BKE Nasdaq
- VRNA Nasdaq
- Market Cap
- BKE 2.4B
- VRNA 2.9B
- IPO Year
- BKE 1992
- VRNA 2017
- Fundamental
- Price
- BKE $47.62
- VRNA $37.86
- Analyst Decision
- BKE Hold
- VRNA Strong Buy
- Analyst Count
- BKE 1
- VRNA 6
- Target Price
- BKE $46.00
- VRNA $43.83
- AVG Volume (30 Days)
- BKE 352.5K
- VRNA 1.1M
- Earning Date
- BKE 11-26-2024
- VRNA 11-04-2024
- Dividend Yield
- BKE 2.96%
- VRNA N/A
- EPS Growth
- BKE N/A
- VRNA N/A
- EPS
- BKE 4.10
- VRNA N/A
- Revenue
- BKE $1,230,712,000.00
- VRNA $5,624,000.00
- Revenue This Year
- BKE N/A
- VRNA N/A
- Revenue Next Year
- BKE $2.67
- VRNA $554.09
- P/E Ratio
- BKE $11.60
- VRNA N/A
- Revenue Growth
- BKE N/A
- VRNA 1127.95
- 52 Week Low
- BKE $34.87
- VRNA $11.39
- 52 Week High
- BKE $49.78
- VRNA $40.13
- Technical
- Relative Strength Index (RSI)
- BKE 63.86
- VRNA 57.91
- Support Level
- BKE $46.10
- VRNA $34.51
- Resistance Level
- BKE $49.78
- VRNA $40.13
- Average True Range (ATR)
- BKE 1.24
- VRNA 2.27
- MACD
- BKE 0.16
- VRNA -0.16
- Stochastic Oscillator
- BKE 71.50
- VRNA 73.40
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to better-priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.